ArticleExperimental and therapeutic medicine2012
Significance of survivin expression: Prognostic value and survival in stage III non-small cell lung cancer.
Article in Experimental and therapeutic medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.BMC cancer · 2016Pooled it
- Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer.Medical oncology (Northwood, London, England) · 2014Trial
- Article
- Review
- Role of Napsin A and Survivin Immunohistochemical Expression in Bronchogenic Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Transcriptome Profiling across Five Tissues of Giant Panda.BioMed research international · 2020Article
- Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.International journal of oncology · 2018Article
- Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.Oncology letters · 2017Article
- CPA4 is a Novel Diagnostic and Prognostic Marker for Human Non-Small-Cell Lung Cancer.Journal of Cancer · 2016Article
- SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.OncoTargets and therapy · 2015Article
- The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.International journal of oncology · 2014Article
- Over-expression of survivin and VEGF in small-cell lung cancer may predict the poorer prognosis.Medical oncology (Northwood, London, England) · 2014Article
- Monitoring survivin expression in cancer: implications for prognosis and therapy.Molecular diagnosis & therapy · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study was designed to determine the levels of survivin expression and identify its clinical significance as a prognostic factor for stage III non-small cell lung cancer (NSCLC). A total of 210 cases of stage III NSCLC were collected and the expression levels of survivin and vascular endothelial growth factor A (VEGF-A) in tumor tissues were investigated using immunohistochemistry (IHC). The medical records of the patients were reviewed to determine the association with clinical course. Of the 210 NSCLC tissues, 112 (53.3%) cases demonstrated positive expression of survivin protein. Coexpression of survivin and VEGF-A was identified. The 5-year survival rate of patients with positive survivin expression was significantly lower compared with the survivin-negative cancer patients (P<0.05). The expression of survivin in NSCLC correlated with tumor size. Survivin and VEGF-A were independent prognostic factors of stage III NSCLC. Survivin protein is a valuable marker of prognosis in stage III NSCLC patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.